Zogenix names new board member
This article was originally published in Scrip
San Diego-based Zogenix, a pharmaceutical company developing products for the treatment of pain-related conditions and central nervous system disorders, has named Dr James B Breitmeyer to its board of directors. Dr Breitmeyer currently serves as president of Bavarian Nordic, a late-stage biotechnology company. He is also executive vice-president of Bavarian A/S, a multinational corporation headquartered in Denmark which specializes in the research, development and manufacturing of vaccines and immunotherapy regimens for biodefense, infectious diseases and oncology. He has also previously served as acting chief medical officer of Zogenix in an advisory capacity.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.